CARDIOL THERAPEUTICS INC-A (CRDL) Stock Earnings & Estimates
NASDAQ:CRDL - CA14161Y2006 - Common Stock
1.06 USD
-0.03 (-2.75%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 80K | -100.00% | 19.485M | 69.355M 255.94% | 148.55M 114.19% | 280.91M 89.10% | 309.81M 10.29% | 399.17M 28.84% | |||||||
| EBITDA YoY % growth | -13.98M -99.43% | -20.46M -46.35% | -38.44M -87.88% | -24.48M -6.97% | -23.46M 28.17% | -32.773M -35.10% | -30.806M 22.80% | -29.36M 4.70% | 28.743M 197.90% | -21.036M -173.19% | 43.525M 306.90% | 142.09M 226.46% | 227.65M 60.22% | 315.38M 38.54% | |
| EBIT YoY % growth | -14.13M -99.01% | -20.69M -46.43% | -38.66M -86.85% | -39.79M -6.93% | -29.07M 27.95% | -40.494M -35.22% | -30.855M 23.39% | -29.702M 3.74% | -14.785M 50.22% | 22.79M 254.15% | 97.246M 326.70% | 220.7M 126.95% | 260.95M 18.24% | 346.35M 32.73% | |
| Operating Margin | N/A | N/A | -48,325.00% | N/A | N/A | N/A | N/A | N/A | -75.88% | 32.86% | 65.46% | 78.57% | 84.23% | 86.77% | |
| EPS YoY % growth | N/A | N/A 12.54% | N/A -10.14% | -0.54 8.50% | -0.44 10.20% | -0.55 -15.91% | -0.37 27.00% | -0.56 -51.60% | -0.10 81.93% | 0.13 224.40% | 0.70 447.91% | 1.74 149.63% | 1.77 1.70% | 2.45 38.73% |
All data in CAD
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.09 49.00% | -0.07 20.67% | -0.11 -12.20% | -0.10 -2.00% | -0.11 -22.22% | -0.11 -57.14% |
| Revenue Q2Q % growth | ||||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -8.364M 40.85% | -9.384M 6.06% | -9.384M -11.33% | -9.486M -1.09% | -10.2M -21.95% | -10.812M -15.22% |
All data in CAD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | -0.10 | -0.12 | 0.02 | 18.30% |
| Q1 2025 Q2Q % growth | -0.10 28.57% | -0.14 | 0.04 | 29.97% |
| Q4 2024 Q2Q % growth | -0.09 25.00% | -0.13 | 0.04 | 32.64% |
| Q3 2024 Q2Q % growth | -0.18 -100.00% | -0.12 | -0.06 | -47.06% |
| Q2 2024 Q2Q % growth | -0.10 16.67% | -0.13 | 0.03 | 24.59% |
| Q1 2024 Q2Q % growth | -0.14 -27.27% | -0.13 | -0.01 | -5.58% |
| Q4 2023 Q2Q % growth | -0.12 | -0.12 | 0.00 | 1.96% |
| Q3 2023 Q2Q % growth | -0.09 30.77% | -0.12 | 0.03 | 26.47% |
| Q2 2023 Q2Q % growth | -0.12 -20.00% | -0.13 | 0.01 | 5.88% |
| Q1 2023 Q2Q % growth | -0.11 21.43% | -0.15 | 0.04 | 28.10% |
| Q4 2022 Q2Q % growth | -0.12 -9.09% | -0.16 | 0.04 | 24.10% |
| Q3 2022 Q2Q % growth | -0.13 8.96% | -0.15 | 0.02 | 12.10% |
| Q2 2022 Q2Q % growth | -0.10 37.50% | -0.14 | 0.04 | 29.97% |
| Q1 2022 Q2Q % growth | -0.14 46.15% | -0.17 | 0.03 | 19.26% |
| Q4 2021 Q2Q % growth | -0.11 26.67% | -0.15 | 0.04 | 28.10% |
| Q2 2021 Q2Q % growth | -0.16 | -0.14 | -0.02 | -12.04% |
| Q1 2021 Q2Q % growth | -0.26 -136.36% | -0.14 | -0.12 | -82.07% |
| Q4 2020 Q2Q % growth | -0.15 -25.00% | -0.12 | -0.03 | -22.55% |
| Q1 2020 Q2Q % growth | -0.11 | -0.16 | 0.05 | 32.60% |
| Q4 2019 Q2Q % growth | -0.12 | -0.13 | 0.01 | 9.50% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2022 Q2Q % growth | -100.00% | % | ||
| Q3 2021 Q2Q % growth | 306K | -306K | -100.00% | |
| Q2 2021 Q2Q % growth | 80K | 204K | -124K | -60.78% |
| Q1 2021 Q2Q % growth | 51K | -51K | -100.00% | |
| Q4 2020 Q2Q % growth | 255K | -255K | -100.00% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 20% | 29.13% | 29.13% |
| Revenue | N/A | N/A | N/A | N/A |